C#SE HP/2-21551/A AND TRADEMARK OFFICE IN THE UNITED STATESURA

IN RE APPLICATION OF

Group Art Unit: 1616

ANDREAS WERNER SUPERSAXO ET AL

Examiner: S. Sharareh

APPLICATION NO: 09/306,006

FILED: MAY 6, 1999

FOR: USE OF NANODISPERSIONS IN

PHARMACEUTICAL END FORMULATIONS

Assistant Commissioner for Patents

Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 CFR 1.56, Applicants wish to call the Examiner's attention to the references cited on the attached form PTO-1449, which references were cited in a communication from a foreign patent office in a counterpart foreign application.

Copies of these references are enclosed herewith along with a copy of the Austrian Search Report.

WO 97/21428 is already of record in the instant application. Abstracts are also included for EP 082437 and DE 19522693.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Certificate under 37 CFR 1.97(e)(1)

I, the undersigned agent, hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Ciba Specialty Chemicals Corporation Patent Department 540 White Plains Road P.O. Box 2005 Tarrytown, NY 10591-9005 (914) 785-7127 KTM/am/ Encl. References

Austrian Search Report

APR 06 2000

Respectfully submitted,

Kévin T. Mansfield Agent for Applicants Reg. No. 31,635